Tag
This large cohort study demonstrates that biologic therapy in pregnant women with psoriasis is not associated with increased adverse pregnancy outcomes and may reduce risks of spontaneous abortion and gestational diabetes.
This study demonstrates that tildrakizumab, an IL-23 inhibitor, partially reverses accelerated epigenetic aging in psoriasis patients, highlighting a novel aspect of biologic therapy beyond skin inflammation control.
A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting
Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and
A 16-week Mediterranean diet intervention significantly reduced psoriasis severity and improved metabolic markers in patients with mild to moderate disease, suggesting diet’s role as adjunctive therapy in psoriasis management.
In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psorias
